APRAMEYA vs BETA: Stock Comparison
BETA DRUGS is the larger company by market capitalisation. APRAMEYA shows lower leverage, while BETA DRUGS shows a lower P/E, a higher ROE and a higher ROCE. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
APRAMEYA leads 5; BETA leads 5 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Price
| Metric | APRAMEYA | BETA |
|---|---|---|
| Live Price | — | ₹2,074.6 |
| Day Change | — | 0.94% |
| Volume | — | 10,479 |
| 52-Week High | — | ₹2,807.9 |
| 52-Week Low | — | ₹990.1 |
| Distance from 52W High | — | -26.12% |
Valuation
| Metric | APRAMEYA | BETA |
|---|---|---|
| Market Cap | ₹219 Cr | ₹2,303 Cr |
| P/E Ratio | 60.82x | 50.76x |
| P/B Ratio | 0x | 8.6x |
| EPS | ₹2.68 | ₹5.35 |
| Book Value | ₹36.54 | ₹220.79 |
| Dividend Yield | 0% | 0% |
Growth
| Metric | APRAMEYA | BETA |
|---|---|---|
| Revenue Growth (TTM YoY) | 0% | 0% |
| EPS Growth (TTM YoY) | 0% | 0% |
| Qtr Sales Growth | 0.7% | -55.53% |
| Qtr Profit Growth | 1.73% | -64.01% |
Profitability & Leverage
| Metric | APRAMEYA | BETA |
|---|---|---|
| ROE | 7.37% | 14.27% |
| ROCE | 10.07% | 18.59% |
| Net Margin | 0% | 10.78% |
| Operating Margin | 19.83% | 18.28% |
| Debt to Equity | 0.1x | 0.87x |
Shareholding
As of Mar 2026 • change vs previous quarter| Metric | APRAMEYA | BETA |
|---|---|---|
| Promoter Holding | 74.05%▲ 0.52 pp | 59.1%▼ 5.53 pp |
| FII Holding | 0% | 1.02%▼ 0.14 pp |
| DII Holding | 0.7%▼ 0.07 pp | 6.23%▲ 4.08 pp |
| Public Holding | 25.24%▼ 0.46 pp | 33.65%▲ 1.59 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: APRAMEYA and BETA DRUGS.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.